UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688

Translational psychiatry, 2015-12, Vol.5 (12), p.e693-e693

2015

Volltextzugriff (PDF)

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders

European neuropsychopharmacology, 2021-07, Vol.48, p.49-88

2021

Volltextzugriff (PDF)

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

Neuroscience, 2010-06, Vol.167 (4), p.1160-1167

2010

Volltextzugriff (PDF)

Restless legs syndrome improved by pramipexole: a double-blind randomized trial

Neurology, 1999-03, Vol.52 (5), p.938-938

1999

Volltextzugriff (PDF)

Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group

The pharmacogenomics journal, 2002, Vol.2 (5), p.284-292

2002

Volltextzugriff (PDF)

Central Nervous System Drug Development: An Integrative Biomarker Approach toward Individualized Medicine

NeuroRx, 2005-10, Vol.2 (4), p.683-695

2005

Volltextzugriff (PDF)

Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys

The Journal of pharmacology and experimental therapeutics, 1991-10, Vol.259 (1), p.409

1991

Volltextzugriff (PDF)

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine

Cephalalgia, 2001-09, Vol.21 (7), p.727-732

2001

Volltextzugriff (PDF)

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys

Clinical neuropharmacology, 1993-10, Vol.16 (5), p.418-427

1993

Volltextzugriff (PDF)

Proteomic Profiling of Cerebrospinal Fluid by 8-Plex iTRAQ Reveals Potential Biomarker Candidates of Alzheimer’s Disease

Clinical proteomics, 2009-06, Vol.5 (2), p.114-124

2009

Volltextzugriff (PDF)

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Brain Structure and Function, 2015-09, Vol.220 (5), p.3043-3051

2015

Volltextzugriff (PDF)

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop

Journal of clinical pharmacology, 2003-04, Vol.43 (4), p.342-358

2003

Volltextzugriff (PDF)

Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes

Journal of Alzheimer's disease, 2008-02, Vol.13 (1), p.17-30

2008

Volltextzugriff (PDF)

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?

Fundamental & clinical pharmacology, 1995-01, Vol.9 (5), p.434-442

1995

Volltextzugriff (PDF)

Ethosuximide and tremor in Parkinson's disease: A pilot study

Movement disorders, 1992, Vol.7 (2), p.132-136

1992

Volltextzugriff (PDF)

Prospective study designs in outcomes research: the case of migraine

PharmacoEconomics, 2002, Vol.20 (11), p.715-725

2002

Volltextzugriff (PDF)

Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine

Cephalalgia, 2001-09, Vol.21 (7), p.727-732

2001

Volltextzugriff (PDF)

Effect of estrogen and progesterone on l-DOPA induced dyskinesia in MPTP-treated monkeys

Neuroscience letters, 1992-01, Vol.135 (1), p.129-132

1992

Volltextzugriff (PDF)

Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan

Clinical therapeutics, 2001, Vol.23 (1), p.127-145

2001

Volltextzugriff (PDF)

N03 Efficacy, Safety, And Tolerability Of Afq056 For The Treatment Of Chorea In Patients With Huntington's Disease

Journal of neurology, neurosurgery and psychiatry, 2014-09, Vol.85 (Suppl 1), p.A102-A104

2014

Volltextzugriff (PDF)

N03Efficacy, Safety, And Tolerability Of Afq056 For The Treatment Of Chorea In Patients With Huntington's Disease

Journal of neurology, neurosurgery and psychiatry, 2014-09, Vol.85 (Suppl 1), p.A102-A104

2014

Volltextzugriff (PDF)

Pathophysiology of L-Dopa-induced dyskinesias

Movement disorders, 1999, Vol.14, p.4-8

1999

Volltextzugriff (PDF)

SMA THERAPIES II AND BIOMARKERS

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S110

2018

Volltextzugriff (PDF)

SMA THERAPIES II AND BIOMARKERS: P.261Safety and efficacy of the oral splice modulator branaplam in type 1 spinal muscular atrophy

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S110-S110

2018

Volltextzugriff (PDF)

Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys

Advances in neurology, 1993, Vol.60, p.113

1993

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(53)
Tagungsberichte
(2)

Sprache

Englisch
(55)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Biological And Medical Sciences
(25)
Medical Sciences
(25)
Neurosciences & Neurology
(23)
Female
(22)
Pharmacology. Drug Treatments
(22)
Humans
(21)
Animals
(19)
Clinical Neurology
(18)
Pharmacology & Pharmacy
(16)
Macaca Fascicularis
(14)
Neuropharmacology
(13)
Male
(12)
Middle Aged
(12)
Anticonvulsants. Antiepileptics. Antiparkinson Agents
(10)
Adult
(9)
Neurosciences
(9)
Parkinson Disease, Secondary - Chemically Induced
(9)
Double-Blind Method
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688

A white paper on a neurodevelopmental framework for drug discovery in autism and other neurodevelopmental disorders

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias

Restless legs syndrome improved by pramipexole: a double-blind randomized trial

Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group

Central Nervous System Drug Development: An Integrative Biomarker Approach toward Individualized Medicine

Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys

Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys

Proteomic Profiling of Cerebrospinal Fluid by 8-Plex iTRAQ Reveals Potential Biomarker Candidates of Alzheimer’s Disease

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA-PWG-PhRMA-DruSafe Workshop

Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes

Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia?

Ethosuximide and tremor in Parkinson's disease: A pilot study

Prospective study designs in outcomes research: the case of migraine

Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine

Effect of estrogen and progesterone on l-DOPA induced dyskinesia in MPTP-treated monkeys

Treatment satisfaction, functional status, and health-related quality of life of migraine patients treated with almotriptan or sumatriptan

N03 Efficacy, Safety, And Tolerability Of Afq056 For The Treatment Of Chorea In Patients With Huntington's Disease

N03Efficacy, Safety, And Tolerability Of Afq056 For The Treatment Of Chorea In Patients With Huntington's Disease

Pathophysiology of L-Dopa-induced dyskinesias

SMA THERAPIES II AND BIOMARKERS

SMA THERAPIES II AND BIOMARKERS: P.261Safety and efficacy of the oral splice modulator branaplam in type 1 spinal muscular atrophy

Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys

Suchergebnisse filtern